FDA panel recommends approval of Paratek's antibiotic

A Food and Drug Administration advisory panel has recommended approval of an experimental medicine, in both intravenous and oral forms, developed by Paratek Pharmaceuticals to treat skin infections and pneumonia. The FDA's Antimicrobials Drug Advisory Committee voted 17-to-1 to recommend approval of the new drug candidate, an antibiotic called omadacycline, for the treatment of acute bacterial skin and skin structure infections. The committee voted 14-4 to recommend approval of omadacycline for…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news